You are here: Industry Insights > Gracell

News List

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer prnasia
May 11, 2021
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Dr. Jenny (Yajin) Ni as its CTO.
Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting prnasia
April 12, 2021
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, presented updated long-term follow-up data on their TruUCAR-enabled ...
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S. prnasia
April 01, 2021
Gracell Biotechnologies Inc. announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza for clinical manufacturing of Gracell's FasTCAR-enabled CAR-T cell product candidates in the U.S.
Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL prnasia
March 31, 2021
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enrolled the first patient in their pivotal ...
China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL prnasia
January 14, 2021
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval for a pivotal seamless Phase 1/2 clinical ...
Gracell Biotechnologies Announces Pricing of Initial Public Offering prnasia
January 08, 2021
Gracell Biotechnologies Inc. announced the pricing of its initial public offering of 11,000,000 American Depositary Shares ("ADSs"), each representing five ordinary shares, at a public offering price of US$19.00 per ADS.
Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mu prnasia
December 07, 2020
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced an interim readout to evaluate the safety and efficacy of ...
Gracell to Present the First-in-human, Universal TruUCAR™ GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting prnasia
April 13, 2020
Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, is pleased to announce that their first-in-human phase I data of Universal TruUCAR™ GC027 in relapsed or refractory (R/R) T-cell acute lymphoblastic leuk
Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia prnasia
April 04, 2020
Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell & gene therapy company, is pleased to announce that China National Medical Products Administration (NMPA) has accepted Gracell's Investigational New Drug (IND) application for GC
Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR™ Therapy for Relapsed or Refractory T-cell Malignancies prnasia
January 09, 2020
Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell therapy company, today announced the initiation of an investigational study of GC027, the first product candidate developed using TruUCAR™ to treat relapsed or refractory (R/R) T-

Previous page 1 2 Next page